NVO - Novo Nordisk lifts guidance as Ozempic Wegovy sales surge; but stock falls 3%
2024-05-02 04:11:57 ET
More on Novo Nordisk
- Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy
- Novo Nordisk Remains The Better Buy After A Moderate Pullback
- Novo Nordisk: The Moat Won't Last Forever
- Novo Nordisk reports Q1 results; updates FY24 outlook
- Novo, AstraZeneca issued FTC warnings over ‘bogus’ patents